---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-126761"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:35:07.955874+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio appoints William Fricker as interim CFO effective December 4, 2024

## Summary
- William Fricker, 61, appointed interim CFO; most recently CFO of NeuroTrauma Sciences (Dec 2023-Apr 2024).
- Previously CFO at NRX Pharmaceuticals (2020-2021), taking it public, and CAO at Immunomedics (2018-2020) until sale to Gilead.
- Fricker served as independent CFO contractor for biotech firms from 2021-2023; CPA (inactive), started career at PwC.
- No related-party transactions; Fricker serves on contract basis without employment agreement.

## SEC filing metadata
- accession: 0001104659-24-126761
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924126761/0001104659-24-126761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924126761/tm2430528d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-126761
- JSON: https://secwatch.observer/filing/0001104659-24-126761.json
- Plain text: https://secwatch.observer/filing/0001104659-24-126761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.